Complete financial analysis of Amylyx Pharmaceuticals, Inc. (AMLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amylyx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Signatureglobal (India) Limited (SIGNATURE.BO) Income Statement Analysis – Financial Results
- NZ Windfarms Limited (NWF.NZ) Income Statement Analysis – Financial Results
- Unieuro S.p.A. (UNIR.MI) Income Statement Analysis – Financial Results
- Holmen AB (publ) (HLMNY) Income Statement Analysis – Financial Results
- Shenzhen SED Industry Co., Ltd. (000032.SZ) Income Statement Analysis – Financial Results
Amylyx Pharmaceuticals, Inc. (AMLX)
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 380.79M | 22.23M | 285.00K | 650.00K | 1.43M |
| Cost of Revenue | 25.44M | 2.99M | 52.00K | 24.59M | 11.90M |
| Gross Profit | 355.35M | 19.24M | 233.00K | -23.94M | -10.47M |
| Gross Profit Ratio | 93.32% | 86.54% | 81.75% | -3,683.69% | -734.43% |
| Research & Development | 128.19M | 93.45M | 44.04M | 24.59M | 11.90M |
| General & Administrative | 178.86M | 127.13M | 38.93M | 15.06M | 3.08M |
| Selling & Marketing | 9.50M | 4.40M | 0.00 | 0.00 | 0.00 |
| SG&A | 188.36M | 127.13M | 38.93M | 15.06M | 3.08M |
| Other Expenses | 0.00 | 3.74M | -285.00K | -650.00K | -1.43M |
| Operating Expenses | 316.54M | 220.58M | 82.69M | 39.01M | 13.55M |
| Cost & Expenses | 341.98M | 223.57M | 82.69M | 39.01M | 13.55M |
| Interest Income | 16.16M | 4.29M | 36.00K | 14.00K | 176.00K |
| Interest Expense | 0.00 | 4.29M | 0.00 | 2.29M | 1.28M |
| Depreciation & Amortization | 1.09M | 487.00K | 52.00K | 1.00K | 13.55M |
| EBITDA | 39.89M | -200.85M | -82.64M | -39.00M | 1.11M |
| EBITDA Ratio | 10.48% | -905.72% | -29,013.33% | -5,957.08% | -938.22% |
| Operating Income | 38.80M | -201.34M | -82.69M | -39.01M | -13.55M |
| Operating Income Ratio | 10.19% | -905.72% | -29,013.33% | -6,000.77% | -950.49% |
| Total Other Income/Expenses | 15.50M | 3.74M | -5.24M | -3.28M | -162.00K |
| Income Before Tax | 54.30M | -197.60M | -87.93M | -42.28M | -13.72M |
| Income Before Tax Ratio | 14.26% | -888.89% | -30,852.98% | -6,504.62% | -961.85% |
| Income Tax Expense | 5.03M | 774.00K | -52.00K | 2.56M | 1.10M |
| Net Income | 49.27M | -198.38M | -87.88M | -44.84M | -14.82M |
| Net Income Ratio | 12.94% | -892.38% | -30,834.74% | -6,898.00% | -1,038.99% |
| EPS | 0.73 | -2.98 | -1.52 | -0.79 | -0.26 |
| EPS Diluted | 0.70 | -2.98 | -1.52 | -0.79 | -0.26 |
| Weighted Avg Shares Out | 67.23M | 66.51M | 57.86M | 56.47M | 56.47M |
| Weighted Avg Shares Out (Dil) | 69.99M | 66.51M | 57.86M | 56.47M | 56.47M |
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK , July 18, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders. According to a federal securities...
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
Amylyx Pharmaceuticals Inc AMLX acquired avexitide from Eiger BioPharmaceuticals Inc EIGRQ for $35.1 million.
Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Avexitide Acquisition Conference Call July 10, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Joshua Cohen - Co-Chief Executive Officer Camille Bedrosian...
This cheap biotech offers investors a play on ALS if trial data continues to impress
NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase...
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Amylyx Pharmaceuticals has agreed to buy the rights to bankrupt drugmaker Eiger BioPharmaceuticals' experimental drug for low blood sugar in a $35.1 million deal, Eiger said in a filing on Friday.
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference.
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
Amylyx Pharmaceuticals, Inc. (AMLX) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of $0.24. This compares to earnings of $0.02 per share a year ago.
Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, and Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, will participate in the 2024 Bank of...
Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its first quarter 2024 financial results on Thursday, May 9, 2024. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m....
Source: https://incomestatements.info
Category: Stock Reports